Holen Sie sich die Stockscreener-App
0.2262
0.22%
-0.0005
Handel nachbörslich:
.22
-0.0062
-2.74%
Schlusskurs vom Vortag:
$0.2267
Offen:
$0.2267
24-Stunden-Volumen:
158.47K
Relative Volume:
0.11
Marktkapitalisierung:
$2.35M
Einnahmen:
$2.88M
Nettoeinkommen (Verlust:
$-5.12M
KGV:
-0.000838
EPS:
-269.9888
Netto-Cashflow:
-
1W Leistung:
-2.79%
1M Leistung:
-1.31%
6M Leistung:
-81.46%
1J Leistung:
-96.58%
1-Tages-Spanne:
$0.22
$0.2267
1-Wochen-Bereich:
$0.2125
$0.25
52-Wochen-Spanne:
$0.2055
$14.22
Scisparc Ltd Stock (SPRC) Company Profile
Vergleichen Sie SPRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SPRC | 0.2262 | 2.35M | 2.88M | -5.12M | 0 | -269.99 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Scisparc Ltd Aktie (SPRC) Neueste Nachrichten
SciSparc Ltd. Reports Changes in Financial Position - TipRanks
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
SciSparc Ltd. Gains Shareholder Approval for Proposals - TipRanks
SciSparc Ltd. Reschedules Annual General Meeting - TipRanks
Examining SPRC’s book value per share for the latest quarter - US Post News
Financial Metrics Unveiled: SciSparc Ltd (SPRC)’s Key Ratios in the Spotlight - The Dwinnex
SPRC Stock Hits 52-Week Low at $0.21 Amid Market Challenges - Investing.com
SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN
SciSparc stock plunges to 52-week low, hits $0.23 - Investing.com India
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome - 420 Intel
SciSparc receives FDA approval for trial for Tourette syndrome therapy - Clinical Trials Arena
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
FDA greenlights SciSparc's Phase IIb Tourette Syndrome study By Investing.com - Investing.com South Africa
Pharmaceutical FDA Next Phase Cannabinoid For TouretteSciSparc (NASDAQ:SPRC) - Benzinga
SciSparc secures FDA approval to launch Phase IIB trial for TS treatment - TipRanks
FDA greenlights SciSparc's Phase IIb Tourette Syndrome study - Investing.com
SciSparc Secures FDA Green Light to US Launch of its - GlobeNewswire
Financial Metrics Check: SciSparc Ltd (SPRC)’s Ratios for Trailing Twelve Months - The Dwinnex
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - StockTitan
SciSparc Ltd (SPRC) stock: A year of ups and downs - US Post News
SciSparc signs LOI to sell entire ownership in MitoCareX - MSN
SciSparc Ltd. Proposes Reverse Stock Split - TipRanks
SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada
SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com
SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire
Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World
Smartgroup Announces Major Shareholding Changes - TipRanks
Science Group PLC Executes Share Buyback - TipRanks
Site Group Plans Massive New Share Issue - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World
Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily
SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat
CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks
Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
Clearmind, SciSparc slide amid weight-loss study results - MSN
FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter
UBS Cuts Stake in Spirent Communications - TipRanks
SThree maintains expectations amid tough market conditions. - Research the market
UK recruiter SThree falls on lower Q3 net fee - XM
SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK
Science Group PLC Announces Share Buyback - TipRanks
SThree plc Navigates Market Headwinds in Q3 - TipRanks
SThree Net Fees Fall Amid Challenging Environment - MarketWatch
Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat
Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World
Finanzdaten der Scisparc Ltd-Aktie (SPRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):